Why the study?
Although type 2 diabetes mellitus and obstructive sleep apnea are independently recognized cardiovascular disease risk factors, little is known about their interaction.
Does active CPAP improve flow-mediated dilation of the brachial artery in adults with type 2 diabetes mellitus and obstructive sleep apnea?
Does active CPAP improve flow-mediated dilation of the brachial artery in adults with type 2 diabetes mellitus and obstructive sleep apnea?
Three months of CPAP therapy did not significantly improve macrovascular endothelial function in patients with concurrent type 2 diabetes and obstructive sleep apnea.
Answers are grounded in this paper and cite their sources.
CPAP does not improve endothelial function in T2DM with OSA; challenges assumptions of vascular benefit and supports reevaluating CPAP indications in this population.
Rationale Although both type 2 diabetes mellitus (T2DM) and obstructive sleep apnea (OSA) are independently recognized as risk factors for cardiovascular disease, little is known about their interaction. Objectives We hypothesized that T2DM and OSA act synergistically to increase vascular risk, and that treatment of OSA would improve vascular reactivity in patients with T2DM plus OSA. Methods Cross-sectional study of 141 adults with T2DM, OSA, T2DM plus OSA, and control subjects, followed by a 3-month, parallel-arm, randomized, placebo-controlled trial comparing active and sham continuous positive airway pressure (CPAP) in 53 adults with T2DM plus OSA. Endothelium-dependent macro- and microvascular reactivity (flow-mediated dilation [FMD] of the brachial artery and acetylcholine-induced dilation of forearm microvasculature, respectively) and cardiovascular magnetic resonance to assess left- and right-ventricular mass/volume. Results Mean (±SD) FMD was 6.1 (±4.0)%, 7.3 (±3.6)%, 6.8 (±4.5)%, and 4.8 (±2.9)% in control subjects, T2DM only, OSA only, and T2DM plus OSA, respectively. We observed a significant T2DM × OSA interaction on FMD, such that the mean effect of OSA in those with T2DM was 3.1% (95% confidence interval [CI], 0.6 to 5.6) greater than the effect of OSA in those without T2DM. A total of 3 months of CPAP resulted in a mean absolute increase in FMD of 0.3% (95% CI, −1.9 to 2.5; primary endpoint), with a net improvement of 1.1% (95% CI, −1.4 to 3.6) among those with adherence of 4 h/night or greater. A significant T2DM × OSA interaction was found for both left ventricular (LV) and right ventricular end-diastolic volume, such that OSA was associated with a 22.4 ml (95% CI, 3.2 to 41.6) greater LV end-diastolic volume and 23.2 ml (95% CI, 2.6 to 43.8) greater right ventricular end-diastolic volume in those with T2DM compared with the impact of OSA in those without T2DM. We observed a net improvement in LV end-diastolic volume of 8.7 ml (95% CI, −7.0 to 24.4). Conclusions The combination of T2DM plus OSA is associated with macrovascular endothelial dysfunction beyond that observed with either disease alone. CPAP for 3 months did not significantly improve macrovascular endothelial function in the intent-to-treat analysis; however, cardiovascular magnetic resonance results suggest that there may be a beneficial effect of CPAP on LV diastolic volume. Clinical trial registered with www.clinicaltrials.gov (NCT01629862).
No takes yet. Share an insight, caveat, or question.
Bakker et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: